He M, Li JJ, Zuo WJ, et al. - Researchers sought to identify the prognostic factors associated with progression-free survival (PFS) in 398 patients with hormone receptor (HR)-positive metastatic breast cancer (MBC) receiving fulvestrant 500 mg at a single center over a 6-year period. They compared the PFS of patients with lung and liver metastases using Kaplan-Meier analysis. Among the participants, 233 patients had baseline visceral metastases, including 138 with lung metastases without liver involvement, 51 with liver metastases without lung involvement and 41 with lung and liver metastases. As per outcomes, patients with lung without liver or nonvisceral metastases benefit from fulvestrant treatment. They recommend differentiating patients with lung metastases from those with liver metastases when providing treatment to HR-positive/human epidermal growth factor receptor 2-negative MBC patients with endocrine therapy.